Drug intelligence / Profile preview

SG-55

Development stage: Unknown
Lead developer: China Pharmaceutical University

Overview

SG-55: sourced facts only. name: "Combining Osimertinib with SG-55, a novel selective AKR1C3 inhibitor, effectively reverses this resistance, restoring sensitivity in NSCLC cells with the C797S mutation." [PMID:41824443]; target: "Combining Osimertinib with SG-55, a novel selective AKR1C3 inhibitor, effectively reverses this resistance, restoring sensitivity in NSCLC cells with the C797S mutation." [PMID:41824443]; developer: "State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, Jiangsu 211198, China." [PMID:41824443]; stage: "Combining Osimertinib with SG-55, a novel selective AKR1C3 inhibitor, effectively reverses this resistance, restoring sensitivity in NSCLC cells with the C797S mutation." [PMID:41824443]

Targets

AKR1C3 (Aldo-keto reductase family 1 member C3)

Beyond the preview

Go deeper on SG-55.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SG-55.